Table 1.
Demographic and clinical characteristics of patients with at least 24 months of follow-up for multidrug resistant (MDR) TB treatment
| Characteristics | N=612 |
|---|---|
| Age, median (IQR) | 27 (22–36) |
| Female, n (%) | 287 (46.9) |
| Previously treated | 603 (98.5) |
| Previous treatments, median (IQR) | 2 (2–3) |
| Confirmed MDR, n (%) | 551 (90.0) |
| Extrapulmonary disease, n (%) | 44 (7.0) |
| Cavitary lesions on radiograph, n (%) | 306/475 (64.4) |
| BMI, median (IQR) (n=521) | 16.6 (14.8–19.1) |
| Haemoglobin (g/dL), median (IQR) (n=555) | 12.7 (10.8–14.4) |
| Cor pulmonale, n (%) | 32 (5.2) |
| Diabetes, n (%) | 33 (5.4) |
| Tobacco smoker, n (%) | 67/576 (11.6) |
| Drug use, n (%) | 37 (6.0) |
| HIV infected, n (%) | 133 (21.7) |
| CD4 count, median cells/m3 (IQR) (n=69) | 239 (143–358) |
| Resistance* | |
| RIF monoresistance, n (%) | 2/355 (0.6) |
| Resistance to INH and RIF only, n (%) | 28/355 (7.9) |
| Resistance to INH, RIF, EMB, SM, n (%) | 242/355 (68.2) |
*Among individuals with phenotypic drug-susceptibility testing performed; remaining participants had molecular resistance testing for INH and RIF only by line probe assay.
BMI, body mass index; EMB, ethambutol; INH, isoniazid; MDR, multidrug-resistant; RIF, rifampin; SM, streptomycin.